Max Planck Institute for Molecular Biomedicine

What Max Planck Institute for Molecular Biomedicine does

Max Planck Institute for Molecular Biomedicine (MPI für molekulare Biomedizin) is a non-profit research institute established in 2001 and headquartered at Röntgenstraße 20, Münster, Germany. It is part of the Max Planck Society (Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.), a German research organization funded primarily by federal and state government contributions. The institute operates three departments — Tissue Morphogenesis (Ralf H. Adams), Functional Genetics (Rui Benedito), and Cell and Tissue Dynamics (Sara Wickström) — alongside multiple independent research groups (e.g., Bedzhov, Miroshnikova, Pitulescu, Rocha) and seven core service facilities covering bioinformatics, bio-optics, electron microscopy, flow cytometry, mass spectrometry, sequencing, and transgenic animal models.

Research is focused on fundamental questions of cell and vascular biology: how cells communicate, organize, and specialize, with emphasis on vascular growth, molecular signaling pathways, and tissue stability. Methodologically, the institute uses interdisciplinary multiscale analyses and develops innovative gene technologies for targeted analysis of gene functions in individual cells. Notable outputs include the discovery of Type R capillaries (published in Nature Cell Biology, 2025), stem cell reprogramming methods using reduced factor cocktails, and a KI-based image analysis approach that generates patient-specific cellular "fingerprints" predictive of prognosis and therapy resistance.

The institute does not operate a commercial revenue model. Its activities are funded through the Max Planck Society's institutional budget augmented by competitive grants (e.g., ERC Synergy Grant 2025) and prize income (e.g., Körber Prize 2026, €1 million). It serves the international scientific community through peer-reviewed publications and conferences, trains PhD students and postdocs via the CiM-IMPRS graduate program and Max Planck Postdoc Program, and conducts public outreach through the MAX-WISSEN portal, Zellux.net, and school programs. No M&A, external investors, or commercial pricing structures are indicated.

Name

Max Planck Institute for Molecular Biomedicine

Legal name

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Website

https://mpi-muenster.mpg.de

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

The Max Planck Institute for Molecular Biomedicine is a non-profit research institute in Münster, Germany, conducting fundamental research on cell and vascular biology across three departments and seven core facilities, serving the international scientific community, PhD/postdoc trainees, and the general public via the Max Planck Society.

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Translational Medicine & Biomarkers (HLAIALAF), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Molecular biomedicine research
• Cell biology research
• Vascular biology research
• Stem cell research
• Fundamental biomedical research

Headquarters

HQ city

Münster

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Distribution channels3 records

Marketing channels7 records

Core offering

The Max Planck Institute for Molecular Biomedicine conducts fundamental research in cell and vascular biology, investigating how cells communicate, organize, and specialize — with a focus on vascular growth, molecular signaling pathways, and tissue stability. It employs interdisciplinary multiscale analyses and develops innovative gene technologies for targeted analysis of gene functions in individual cells. The institute also trains doctoral and postdoctoral researchers through structured graduate and fellowship programs.

Product overview

Max Planck Institute for Molecular Biomedicine is a research institution consisting of three main departments (Tissue Morphogenesis, Functional Genetics, and Cell and Tissue Dynamics), multiple independent research groups, and seven core service facilities (Bioinformatics, BioOptics, Electron Microscopy, Flow Cytometry, Mass Spectrometry, Sequencing, and Transgenic Laboratory). The institute focuses on fundamental research in cell and vascular biology, including how cells communicate, organize, and specialize with a focus on vascular growth, molecular signaling pathways, and tissue stability. The institute also operates educational programs including a graduate school (CiM-IMPRS) and postdoctoral fellowships, and maintains public education resources including MAX-WISSEN and Zellux.net for schools.

Differentiator

Problem solved

Functional benefit

Brands

• MTZ®-MPI-Award: Annual scientific award for young research talents at the institute, endowed with 2,500 euros by the MTZ®-Stiftung since 2009.

Products and services

• CiM-IMPRS Graduate Program
• Max Planck Postdoc Program

Quantifiable outcome

• Discovery of Type R capillaries with role in bone remodelling published in Nature Cell Biology
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Four partnerships are on record, tiered minor.

• German Stem Cell NetworkminorStrategic or Co-development Partner · 1 October 2008Collaborated in developing the 'Stammzellen verstehen' (Understanding Stem Cells) teaching series, providing fact-checked knowledge about stem cells for upper secondary school students
• Schering StiftungminorStrategic or Co-development Partner · 1 October 2008Partnered with German Stem Cell Network and MPI to create educational materials on stem cells for schools, combining scientific expertise with educational outreach experience
• Stammzellnetzwerk.NRWminorStrategic or Co-development Partner · 1 October 2008Network providing diverse offerings for schools including workshops, research lab insights, and digital materials on stem cell topics
• Church, Ethics, Didactics and Medicine InstitutionsminorStrategic or Co-development PartnerVarious institutions from church, ethics, didactics, and medicine sectors collaborated with MPI to develop the Zellux.net web portal on stem cell research

Recent moves6 records

Expansion highlights5 records

Direct peers

• Max Planck Institute for Molecular Genetics: Another Max Planck Society institute conducting fundamental molecular and genetic research in Berlin. Highly comparable as a same-network, non-profit, basic-research institute in molecular biomedicine with similar funding model, department structure, and graduate programs.
• Whitehead Institute for Biomedical Research: MIT-affiliated non-profit biomedical research institute in Cambridge, MA. Comparable as a non-university-based, non-profit research organization running small PI-led labs focused on fundamental molecular and cell biology, with similar output profile of high-impact publications.
• Max Planck Institute for Heart and Lung Research: Max Planck Society sister institute focused on cardiovascular and pulmonary research. Comparable in mandate (vascular biology, Max Planck funding model, ~100-200 staff) and in scope of organ-system-specific molecular biomedicine, with overlapping PI interests in vascular patterning.
• Francis Crick Institute: UK-based biomedical discovery institute with ~1,500 scientists focused on fundamental biology underlying health and disease. Highly comparable in scale-of-ambition, multi-department structure, and translation-adjacent basic research focus on cell biology, vascular biology, and stem cells.
• European Molecular Biology Laboratory (EMBL): Intergovernmental basic-research organization covering molecular biology across multiple sites. Directly comparable as a publicly funded, non-profit molecular life sciences research institute producing high-impact publications and training PhDs/postdocs with shared core facility infrastructure.
• Wellcome Sanger Institute: UK-based genomic and cellular biology research institute. Comparable as a non-profit, well-funded research entity generating large-scale molecular datasets, single-cell profiling, and cell biology discoveries with shared infrastructure and training programs.
• Broad Institute of MIT and Harvard: Non-profit biomedical and genomic research institute. Comparable as a non-profit research entity generating large-scale molecular biology datasets, single-cell analyses, and disease-focused discovery work with similar publication and core facility model.
• Helmholtz Centre for Infection Research: German public large-scale research center focused on infection biology and molecular medicine. Comparable as a publicly funded German life sciences research center with similar core facility infrastructure and translational orientation.
• Allen Institute for Cell Science: Non-profit research institute focused on dynamic cell biology, organoid models, and AI-driven image analysis. Directly comparable in cell biology focus, use of AI/ML image analysis, and non-profit research structure.

Broad incumbents

• Karolinska Institutet: Sweden's largest medical university with extensive biomedical and translational research. Comparable as a publicly funded European biomedical research organization producing high-impact cell and vascular biology research, but operating at much larger academic scale with broader medical school mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/max-planck-institute-for-molecular-biomedicine

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Max Planck Institute for Molecular Biomedicine